BRETT L. ECKER, MD

Plain English
This study looked at how accurate cancer diagnosis data is by comparing information from cancer registries and electronic health records for patients with colorectal liver metastasis. They found that the two sources agreed on diagnoses only 66% of the time, with cancer registries misdiagnosing 9% of cases and having incorrect information about the stage of cancer in 16% of cases. These findings show that relying on real-world data may lead to mistakes in understanding and treating metastatic cancer. Who this helps: This benefits doctors and healthcare providers by highlighting the need for more accurate data when treating patients with metastatic cancer.

Plain English
This study examined how well radiologists agree on measuring the size of pancreatic tumors in patients being treated before surgery. The researchers found that without assistance, the agreement among radiologists on tumor measurements was low, but when they used image registration technology, the agreement improved significantly, with a reliability score of 0.81 for all readers compared to only around 0.43 before (a higher score means better agreement). This is important because it can lead to more accurate assessments of how well treatments are working, ultimately improving patient care. Who this helps: This helps doctors and patients with pancreatic cancer by providing clearer measurements and treatment responses.

Plain English
This study looked at the surgical treatment options for patients with sarcomas that have spread to the liver, focusing on gastrointestinal stromal tumors (GIST), which are the most common type of these cancers in the liver. It found that patients with GIST who were treated with a drug called imatinib before surgery had a 40% chance of surviving for ten years after their surgery. Improving treatment options for other types of sarcomas will rely on developing better therapies tailored to specific cancer types. Who this helps: Patients with sarcoma, especially those with gastrointestinal stromal tumors.

Plain English
This study looked at how different levels of liver therapies aimed at curing colorectal cancer that has spread to the liver affected patients' survival rates. Researchers analyzed data from nearly 35,000 patients and found that increasing the rate of these therapies by just 5% led to a 1.2% increase in survival rates. This is important because it shows that getting more patients access to these curative treatments can significantly improve their chances of living longer. Who this helps: This helps patients with colorectal cancer liver metastases.

Plain English
This study examined how effective adjuvant chemotherapy (a type of treatment given after surgery) is for patients with ampullary adenocarcinoma, a rare cancer. Researchers looked at 183 patients and found that while most received chemotherapy (130 patients), it didn't significantly improve overall survival for everyone; for example, patients who had surgery alone lived about the same time (around 50.9 months) as those who received chemotherapy (around 53.8 months). However, for specific groups: patients with tumors originating in the pancreas or distal bile duct benefited from chemotherapy, living an average of 78.2 months compared to just 22.7 months for those who didn't receive it. Who this helps: This research benefits doctors and oncologists in tailoring treatment plans for patients with ampullary adenocarcinoma.

Plain English
This study looked at how many liver surgeons are available to treat older patients with colorectal cancer that has spread to the liver. Researchers found that there were only 421 surgeons for about 16,700 patients, meaning many people (42.4%) lived where there were no liver surgery options. Those living near a liver surgeon had a better chance of receiving an evaluation and a reduced risk of death, showing that access to surgeons directly affects patient survival. Who this helps: This helps patients with colorectal cancer liver metastases by improving their chances of getting necessary treatments.

Plain English
This study looked at how changes in the SMAD4 gene affect outcomes for patients with localized pancreatic cancer who were treated with two different chemotherapy options. Researchers found that about 27% of patients had changes in the SMAD4 gene, and those with these alterations were nearly twice as likely to experience cancer spread and less likely to have successful surgery when treated with the FOLFIRINOX chemotherapy regimen. This information is important because it can help doctors choose the best chemotherapy option for their patients based on SMAD4 status, potentially improving treatment success rates. Who this helps: Patients with localized pancreatic cancer.

Plain English
This study looked at how radiation therapy can help treat biliary tract cancers, which include types like cholangiocarcinoma and gallbladder cancer. The researchers found that radiation therapy can improve survival for patients, especially those with serious features of their disease; however, since these cancers are rare, most research so far has been small and not very rigorous. Improving radiation treatment could help more patients live longer and feel better, especially those who can’t have surgery. Who this helps: This helps patients with biliary tract cancers and their doctors.

Plain English
This study looked at how adjuvant chemotherapy affects patients with Stage II-IV colorectal cancer after they have had surgery to remove tumors. Researchers found that patients who received chemotherapy had significantly lower rates of cancer returning within the first year compared to those who only had surgery: 9% experienced a return of cancer within the first six months, compared to 22% in the surgery-only group. Chemo helped more in the short term, but the differences in outcomes became smaller after the first year. Who this helps: This research benefits colorectal cancer patients by highlighting the importance of chemotherapy in preventing early recurrence.

Plain English
This study looked at how race and ethnicity affect the likelihood of finding invasive tumors in patients undergoing surgery for a precancerous condition of the pancreas called intraductal papillary mucinous neoplasms. Out of 4,505 cases examined, 20.5% had invasive cancer, with Black patients at 24.2%, Asian patients at 23.7%, and Hispanic patients at 22.6%, compared to 19.9% for non-Hispanic White patients. This difference in invasive cases can't be explained by overall health or age factors, which means that non-White patients face higher risks, and recognizing this can help doctors improve early interventions and treatment strategies. Who this helps: This helps patients from diverse racial and ethnic backgrounds facing pancreatic cancer risks.

Plain English
This study looked at two types of appendiceal cancer—mucinous and non-mucinous—and how much of the tumor needs to be surgically removed to improve survival. Out of nearly 4,700 patients, 68% had their entire colon removed, and while this helped patients with non-mucinous cancer (especially those with medium to high tumor grades), it didn't improve survival for those with mucinous cancer at all. This finding suggests that patients with mucinous appendiceal adenocarcinoma might not need such extensive surgery, which could reduce unnecessary procedures and their associated risks. Who this helps: This helps patients with mucinous appendiceal cancer by potentially sparing them from more invasive surgery.

Plain English
This study examined how neighborhood wealth affects young adults (under 50) with colorectal cancer. It found that those living in poorer neighborhoods were 13% more likely to have advanced cancer when diagnosed and had a 45% higher risk of dying compared to those from wealthier areas. Additionally, non-Hispanic Black patients faced more severe outcomes, including being less likely to have surgery and having lower survival rates. Who this helps: This research benefits patients, particularly young adults with colorectal cancer and those from low-income or minority communities.

Plain English
This study looked at how different KRAS gene mutations affect pancreatic cancer in 1,360 patients who had surgery. They found that a specific mutation (referred to as KRAS) was more common in patients with early-stage cancer and linked to better survival rates—specifically, these patients had fewer recurrences of the cancer. Understanding these differences is important because it can help doctors tailor treatments based on the specific type of mutation a patient has. Who this helps: This helps patients with pancreatic cancer by guiding more personalized treatment options.

Plain English
This study looked at a type of cancer called ampullary adenocarcinoma (AA) and tested a new genomic tool to more accurately predict patient outcomes after treatment. Researchers analyzed data from 192 patients and found that, unlike current standard methods, this genomic classifier could better estimate survival rates based on the cancer's unique biological makeup. For example, patients with tumors that had a higher colorectal genomic profile had better survival odds, while those with pancreatic profiles had worse outcomes. Who this helps: This information benefits doctors and researchers by providing better tools to predict patient outcomes, leading to more tailored treatment plans.

Plain English
Researchers looked at whether hospitals that perform more of a specific cancer surgery (called CRS/HIPEC, which involves removing tumors and bathing the abdomen with heated chemotherapy) get better results than hospitals that do fewer of these operations. They examined over 5,000 procedures across 149 hospitals between 2020 and 2022. They found no meaningful difference in patient outcomes—including complications, deaths, hospital stays, or readmissions—regardless of whether a hospital performed 4 cases a year or 47 cases a year. The only minor difference was that low-volume hospitals sent more patients to the ICU after surgery, but this didn't translate to worse overall results. This matters because it shows that for this particular procedure, hospitals don't need to do hundreds of these surgeries to get good results—experience at a basic level is apparently enough, at least in well-equipped academic medical centers.

Plain English
Researchers tracked cancer surgeries for the pancreas and liver during COVID-19 to see if the pandemic disrupted treatment. They found that pancreatic cancer surgeries continued at normal rates throughout the pandemic, while liver cancer surgeries dropped briefly at the start but quickly returned to normal levels—and more pancreatic cancer patients received chemotherapy before surgery during the pandemic. This matters because it shows hospitals prioritized cancer operations during COVID-19, meaning patients with these deadly cancers didn't face major treatment delays, though the increased use of pre-surgery chemotherapy suggests doctors may have changed their approach to managing these patients.

Plain English
This study looked at different shapes of the main pancreatic duct in patients with a specific type of tumor called intraductal papillary mucinous neoplasm (IPMN) to see if these shapes affect the risk of cancer and how much of the pancreas needs to be removed during surgery. Among 214 patients, more than half (54.2%) had high-grade dysplasia or pancreatic cancer linked to the size and shape of the duct: larger ducts had a higher risk of cancer, with nearly all those with ducts 20 mm or larger being at risk (95.8%). This research is important because it helps doctors understand when limited surgery can be safely performed, potentially sparing patients from more extensive operations while still effectively managing their disease. Who this helps: Doctors treating patients with main-duct-involved IPMN.

Plain English
This study looked at how certain genetic changes in tumors might help predict how well patients with localized pancreatic cancer respond to two specific chemotherapy treatments: FOLFIRINOX and gemcitabine/nab-paclitaxel. Researchers found that changes in the SMAD4 gene were linked to a higher risk of cancer spreading (30% with SMAD4 changes compared to 14.5% without) and a lower chance of being able to surgically remove the tumor (37.1% with SMAD4 changes versus 66.7% without) for those receiving FOLFIRINOX. This research is important because it could help doctors choose the best treatment based on a patient's genetic profile. Who this helps: This helps patients with localized pancreatic cancer and their doctors in making more informed treatment decisions.

Plain English
This study looked at a way to better understand how pancreatic cancer responds to treatment by using advanced imaging techniques. Researchers analyzed images from 30 patients who underwent chemotherapy before surgery, discovering that changes in tumor size measured through these techniques were strongly linked to longer survival rates—specifically, patients with better imaging results had a higher chance of surviving for 5 years without the cancer returning. This new method of measuring tumors can give doctors better tools to predict outcomes and tailor treatments for patients. Who this helps: This helps patients with pancreatic cancer who are undergoing treatment and their doctors in making more informed decisions.

Plain English
This research looked at the link between specific genetic changes (mutations) and how they affect the behavior of pancreatic cancer cells in tumors from 321 patients. The study found that 26.8% of the patients had these mutations, and while some were linked to poorer survival rates, especially in specific conditions, the mutations themselves did not affect the cancer's characteristics or patient outcomes. This means more targeted clinical trials are needed to improve treatment for pancreatic cancer. Who this helps: This helps patients with pancreatic cancer and their doctors by identifying the need for better treatment options.

Plain English
This study looked at ampullary adenocarcinoma, a rare cancer type affecting less than 1% of gastrointestinal cancers, with about 6 new cases diagnosed per million people. Researchers found that tumors classified as the intestinal subtype generally have better survival rates compared to those of the pancreatobiliary subtype, but past studies on this have shown mixed results. Understanding the genetic makeup of these tumors may help in developing more effective treatments tailored to individual patients' needs. Who this helps: Patients with ampullary adenocarcinoma and their doctors.

Plain English
This study looked at a rare case of a 45-year-old woman who had liver masses that appeared cancerous but were actually caused by a parasitic infection transmitted through contaminated soil. After treatment with ivermectin for two weeks, her liver issues completely resolved. This is important because it shows that doctors should consider parasitic infections when diagnosing liver problems, as early treatment can lead to better outcomes and avoid unnecessary surgeries. Who this helps: This helps patients with unexplained liver issues and doctors diagnosing similar cases.

Plain English
This study explored the risk of developing pancreatic fistulas after surgery called pancreatoduodenectomy, analyzing data from over 5,500 patients. Researchers identified 80 different patient scenarios and found that the overall rate of complications was 13.6%. Specifically, certain surgical methods significantly reduced complications, with one approach lowering the risk from 35.5% to 10.7%. Understanding these risks allows doctors to tailor their treatment based on individual patient profiles, improving patient care and outcomes. Who this helps: This research benefits patients undergoing pancreatic surgery and their surgeons by guiding treatment decisions to prevent complications.

Plain English
This study looked at patients with colorectal liver metastasis who had surgery and whether identifying certain genetic changes in their tumors could help choose better treatments. The researchers found that patients in the low-risk genomic group who received a specific chemotherapy treatment had a better chance of surviving, with a 5-year survival rate of 89% compared to 68% for those who didn't receive this treatment. This matters because it shows that using genetic information can help doctors select the most effective therapies for patients, potentially improving outcomes. Who this helps: This helps patients with colorectal liver metastasis and their doctors.

Plain English
This study looked at a new way to conduct randomized clinical trials (RCTs) in surgery using existing health data registries, which are collections of patient information. The researchers developed the first trial using the ACS-NSQIP registry and found that using these databases can provide reliable data without the high costs of traditional trials. This is important because it offers a faster and cheaper way to gather important information that doctors need to make better treatment decisions. Who this helps: This helps doctors and patients by providing better evidence for surgical care.

Plain English
This study looked at how the environment of the lungs in older people affects dormant melanoma cells, which are cancer cells that can remain inactive for years before becoming active again. The researchers found that the aged lung environment helps these dormant melanoma cells grow, while the aged skin seems to prevent this growth. They discovered that a protein called WNT5A plays a key role in allowing these cancer cells to wake up and spread in the lungs when the environment changes with age. Who this helps: This research benefits patients with melanoma by providing insights into how their cancer may reactivate in the lungs, informing future treatment approaches.

Plain English
This study looked at how specific genetic changes in patients with localized pancreatic cancer affected their response to the chemotherapy treatment FOLFIRINOX. Among the 196 patients studied, most had changes in certain genes, with 87.8% showing alterations in the KRAS gene and 66.8% in the TP53 gene. Notably, patients with changes in the SMAD4 gene were less likely to successfully have surgery (only 27.8% could have surgery compared to 59.4% without this alteration) and had a higher risk of cancer spreading during treatment (about 3 times more likely to develop metastasis). Who this helps: This information helps doctors understand which patients may need different treatment approaches based on their genetic makeup.

Plain English
This study examined how well "recurrence-free survival" (the time a patient remains free from cancer after surgery) predicts "overall survival" (the total time a patient lives after treatment) for patients with colorectal liver metastases, which is when cancer spreads from the colon to the liver. Researchers analyzed data from 2,983 patients and found that while the average recurrence-free survival was 1.3 years and overall survival was 5.2 years, the two measures were not strongly correlated. This matters because relying on recurrence-free survival as a benchmark could mislead treatments and patient expectations. Who this helps: This research helps doctors and patients understand the limitations of current measures when assessing cancer treatment outcomes.

Plain English
This study looked at how to treat rare tumors called sarcomas that spread to the liver, focusing on a specific type called gastrointestinal stromal tumor (GIST). It found that patients with GIST who received a treatment called imatinib before surgery had a 40% chance of surviving for at least 10 years if their tumors responded to the treatment. This is important because it shows that surgery can be effective for some patients and highlights the need for better treatments for other types of sarcomas. Who this helps: This benefits patients with metastatic GIST and their doctors.

Plain English
This study looked at a type of immune cell called myeloid-derived suppressor cells (MDSC) in melanoma tumors to understand their role in spreading cancer. The researchers found that these cells produce a protein called Wnt5A, which helps the cancer spread and also supports the immune-suppressing actions of the MDSC. When Wnt5A was removed from these cells, there were fewer MDSC and less immune suppression, leading to decreased cancer spread to the lungs. Who this helps: This benefits melanoma patients by offering insights into potential new treatments that could stop cancer from spreading.

Plain English
Researchers studied ampullary adenocarcinoma, a type of cancer, to find out how its different genetic features could help doctors make better diagnoses and treatment plans. They analyzed data from 3,411 patients to develop a new genetic test that distinguishes between different subtypes of the cancer and found that patients with a colorectal subtype had better survival rates compared to those with a pancreatic subtype, with a 73% agreement between tissue samples and genetic classifications. This research matters because it provides a clearer understanding of the cancer’s diversity, leading to more personalized and effective care for patients. Who this helps: Patients with ampullary adenocarcinoma.

Plain English
This study looked at the effects of surgery on patients with metastatic pancreatic neuroendocrine tumors (PNET) and how a blood marker called chromogranin A (CgA) relates to survival. Researchers analyzed data from 1,478 patients and found that those with metastatic PNET had a median CgA level of 169 ng/mL, which was significantly higher than those without metastasis (66 ng/mL). The study showed that surgery for metastatic PNET improved overall survival for patients who were grouped based on their CgA levels and other factors. Who this helps: This benefits patients with metastatic PNET by providing clearer insights on the importance of surgery in their treatment.

Plain English
This study looked at the best ways for surgeons to perform pancreatic head surgery on patients who have already had a Roux-en-Y gastric bypass for obesity. It involved 96 patients with this prior surgery and found that their recovery and outcomes were similar to those of over 5,500 patients without prior bypass surgery, indicating that the surgical approach is safe and effective. The research also showed that the different methods used to reconnect parts of the digestive system after surgery did not lead to better results, which simplifies options for surgeons. Who this helps: This helps patients facing pancreatic surgery after gastric bypass and their doctors by providing insight into safe surgical practices.

Plain English
This study looked at the safety of performing a specific type of surgery called pancreatoduodenectomy (PD) on patients with high levels of bilirubin in their blood, a condition known as hyperbilirubinemia. Researchers analyzed data from 803 surgeries and found that patients with bilirubin levels of 13 mg/dL or higher had a significantly increased risk of dying within 90 days after the surgery (8 times more likely). The study highlights the importance of addressing high bilirubin levels before surgery to reduce risks and improve patient outcomes. Who this helps: This information helps doctors make better decisions about surgery for patients with high bilirubin levels.

Plain English
This study explored how a protein called p53 can make melanoma, a serious skin cancer, more resistant to treatments. The researchers found that when p53 is kept active, it helps cancer cells enter a slow-growing state that makes them harder to kill—this happens even after therapies that usually work against melanoma. Specifically, using a p53 blocker can make these resistant cells more responsive to treatment, potentially improving outcomes for patients. Who this helps: Patients with metastatic melanoma who struggle to respond to standard therapies.

Plain English
Researchers studied how aging affects melanoma cells' ability to resist treatment. They found that older fibroblasts produce more lipids, particularly ceramides, which help melanoma cells survive targeted therapies by increasing lipid uptake through a transporter called FATP2. Blocking FATP2 in these cells not only stops this lipid accumulation but also improves the effectiveness of treatments, extending survival in older animals by preventing tumor relapses. Who this helps: This benefits older melanoma patients who often struggle with treatment resistance.

Plain English
This study focused on understanding how long patients with a rare cancer called ampullary adenocarcinoma (AAC) might survive after surgery to remove the tumor. Researchers looked at data from over 1,400 patients and found that survival rates varied widely based on factors like age and tumor characteristics, with 5-year survival rates of 81% for low-risk patients and only 14% for those at very high risk. This new prediction tool helps doctors provide better guidance on treatment options and survival expectations for AAC patients. Who this helps: Patients and their doctors.

Plain English
This study looked at how patients' weights change after surgery to remove part of the pancreas (pancreatectomy). Researchers found that, on average, patients lost about 6.6% of their body weight one year after the surgery, with those undergoing proximal pancreatectomy losing more weight than those with distal pancreatectomy. Key factors influencing recovery included age, weight before surgery, and whether patients received nutritional support before the operation; for instance, younger patients and those who were not obese tended to regain weight better. Who this helps: This research benefits doctors and patients by providing insights into which patients may struggle with weight loss after surgery and need additional nutritional support.

Plain English
This study looked at how age affects the treatment of melanoma, specifically focusing on a medication called bevacizumab (Avastin), which targets blood vessel growth. Researchers found that older melanoma patients don’t benefit much from bevacizumab, with younger patients experiencing improved survival rates. This is concerning because while the usual target (VEGF) decreases with age, another factor (sFRP2) actually increases, making the cancer grow more aggressively. Who this helps: This helps older melanoma patients who may not respond well to current treatments.

Plain English
This study looked at how obesity affects breast cancer recurrence and the presence of leftover cancer cells after treatment. Researchers used mice on a high-fat diet and found that those classified as obese had a much higher risk of cancer returning—surviving only 53 days without relapse, compared to 87 days for lean mice and 80 days for those on a low-fat diet. The obese mice also had more residual tumor cells, with an average of 12,550 cells compared to 7,339 in lean mice and 4,793 in those on a low-fat diet. Who this helps: This research helps patients with breast cancer and doctors treating them, especially those focusing on obesity’s role in cancer outcomes.

Plain English
This study focused on grade B pancreatic fistula (B-POPF), a complication that can occur after pancreatic surgery. Researchers found that B-POPF developed in 16.4% of patients, and those affected often required a mix of treatments, including antibiotics in 70.3% of cases and prolonged drainage in 67.8% of cases. The study identified three subclasses of B-POPFs, which showed that as the severity increased, so did the clinical and economic challenges, with subclass B1 being the least severe (19.1%) and B3 being the most severe (28.8%). Who this helps: This research benefits doctors and healthcare providers by improving management strategies for patients with B-POPF.

Plain English
This study looked at whether additional treatment after surgery for ampullary adenocarcinoma, a rare type of cancer, can help patients live longer. Researchers analyzed data from 357 patients who had surgery to remove their cancer and found that those with a specific type of cancer (intestinal subtype) lived a median of 77 months, while those with a different type (pancreatobiliary subtype) lived only 54 months. However, adding treatments like chemotherapy or radiation did not improve survival rates for either type of cancer. Who this helps: This research helps patients with ampullary adenocarcinoma and their doctors by clarifying the role of additional treatments after surgery.

Plain English
This study looked at trends in how soft tissue sarcomas (a rare type of cancer) were treated and the survival rates of patients in the U.S. over ten years. Researchers found that while the use of radiation therapy before surgery increased from 26.6% to 34.8%, the overall survival rate did not change nationally. However, patients treated at high-volume hospitals (those treating many sarcoma patients) had better outcomes, including a higher chance of successful tumor removal and improved survival rates compared to those treated at low-volume hospitals. Who this helps: This research benefits patients with soft tissue sarcomas by highlighting the importance of seeking treatment at specialized hospitals.